TEM8-targeted antibody or antigen-binding fragment thereof, and use thereof

By developing highly specific and bioactive TEM8 antibodies and their antigen-binding fragments, the shortcomings of existing TEM8 antibodies have been overcome, achieving highly efficient targeted killing of TEM8-positive cells and potential anti-tumor therapeutic effects.

WO2024245342A1PCT designated stage expired Publication Date: 2024-12-05INXMED (NANJING) CO LTD

Patent Information

Application Number
PCT/CN2024/096348
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

There is a lack of TEM8 antibodies with high specificity, high bioactivity and high endocytosis capacity in the existing technology, especially in the development of anti-human TEM8 antibodies for the preparation of ADCs and CAR-T.

Method used

An antibody targeting TEM8 and its antigen-binding fragment were developed, which can bind to TEM8 with high affinity, induce endocytosis in TEM8-positive cells, and be used to construct antibody-drug conjugates to target and kill TEM8-positive cells.

Benefits of technology

It achieves highly efficient targeted killing of TEM8-positive cells, has potential anti-tumor therapeutic effects, and can be used to prepare ADC and CAR-T cell therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024096348-FTAPPB-I100001
    Figure PCTCN2024096348-FTAPPB-I100001
  • Figure PCTCN2024096348-FTAPPB-I100002
    Figure PCTCN2024096348-FTAPPB-I100002
  • Figure PCTCN2024096348-FTAPPB-I100003
    Figure PCTCN2024096348-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention belongs to the field of antibodies; and specifically relates to a TEM8 binding molecule, especially an antibody the specifically recognizes TEM 8, and a fragment thereof. Furthermore, the present invention also relates to a nucleic acid or host cell comprising the antibody or the fragment thereof, a drug comprising the antibody or the fragment thereof, and a treatment and diagnostic method using the antibody or the fragment thereof, or the use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

An antibody or antigen-binding fragment targeting TEM8 and its application

[0001] This application is based on the Chinese patent application with application number 202310636114.4 and application date May 31, 2023, and claims the priority of the Chinese patent application. The entire content of the Chinese patent application is hereby introduced into this application as a reference. Technical Field

[0002] The present invention belongs to the field of antibodies and specifically relates to a TEM8-binding molecule, particularly an antibody and fragments thereof that specifically recognize TEM8. Furthermore, the present invention relates to nucleic acids or host cells containing such antibodies or fragments thereof, medicaments containing such antibodies or fragments thereof, and therapeutic and diagnostic methods or uses utilizing such antibodies and fragments. Background Art

[0003] Angiogenesis, the development of new blood vessels from pre-existing capillaries or post-capillary veins, is crucial for a variety of physiological processes, including organ growth, embryonic development, and wound healing. Angiogenesis also plays a crucial role in many diseases, particularly in the development and growth of tumors, which require an adequate blood supply to sustain their growth. Croix et al. compared the gene expression profiles of vascular endothelial cells in normal and tumor tissues and discovered that 46 genes were highly expressed in tumor endothelial cells, hence the name Tumor Endothelial Marker (TEM). TEM8, in particular, showed excellent tumor specificity (Croix BS, Rago C., Velculescu V., Traverso G., Romans KE, Montegomery E., Lal A., Riggins GJ, Lengauer C., Vogelstein B., et al. Genes expressed in human tumor endothelium. Science. 2000; 289:1197–1202. doi:10.1126 / science.289.5482.1197.). TEM8 was soon discovered to be a receptor for anthrax toxin, also known as anthrax toxin receptor 1 (ANTXR1). It shares 58% homology with another anthrax toxin receptor, CMG2 (ANTXR2).

[0004] TEM8 has five splice variants: V1, V2, V3, V4, and V5. They share the same N-terminal sequence, differing primarily in the length of the C-terminal splice (Vargas M., Karamsetty R., Leppla SH, Chaudry GJ. Broad Expression Analysis of Human ANTXR1 / TEM8 Transcripts Reveals Differential Expression and Novel Splizce Variants. PLoS ONE. 2012;7:e43174.doi:10.1371 / annotation / cebf633f-19e7-496b-b370-c0f1b1aea888.). V1 is the predominant splice variant, comprising 564 amino acids and representing the full-length TEM8 sequence. Amino acids 322-342 belong to the transmembrane domain. V2, V3, V4, and V5 have 368, 333, 528, and 358 amino acids, respectively. Therefore, V2 and V4 possess transmembrane domains and, like V1, are membrane proteins. V3 and V5 lack transmembrane domains and are soluble proteins. Furthermore, TEM8 is highly evolutionarily conserved, with the same amino acid sequence in humans and cynomolgus macaques, and the sequences in mice and rats are also completely identical. The homology between humans and mice is 98.9%.

[0005] TEM8 is significantly overexpressed in a variety of tumor tissues, including breast, colorectal, lung, esophageal, gastric, pancreatic, and ovarian cancers. Further studies have revealed that TEM8 is primarily expressed in tumor-associated endothelial cells, perivascular cells, and tumor-associated fibroblasts (Szot C, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927–2943. doi:10.1172 / JCI120481.). TEM8 has also been reported to be expressed in some tumor cells, and nutrient deprivation in the tumor microenvironment can further increase TEM8 expression in tumor-associated fibroblasts. Furthermore, these solid tumors often exhibit a prominent stromal reaction, such as the so-called "desmoplastic stroma" or "reactive stroma," which accounts for 20–60% of the total tumor mass and is characterized by the presence of abundant stromal cells and a dense extracellular matrix (BCM).

[0006] TEM8 binds to collagens I and VI, helping tumor-associated fibroblasts migrate along the collagen fibers of the tumor matrix (Nanda A., Carson-Walter EB, Seaman S., Barber TD, Stampfl J., Singh S., Vogelstein B., Kinzler KW, St Croix B. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI) Cancer Res. 2004; 64: 817–820. doi: 10.1158 / 0008-5472.can-03-2408). According to the latest report, under the condition of nutrient deficiency in the tumor microenvironment, tumor-associated fibroblasts take up collagen fibers through TEM8, convert them into glutamine, and promote tumor cell growth (Hsu K.-S., Dunleavey JM, Szot C., Yang L., Hilton MB, Morris K., Seaman S., Feng Y., Lutz EM, Koogle R., et al. Cancer cell survival depends on collagen uptake into tumor-associated stroma. Nat. Commun. 2022; 13:7078. doi: 10.1038 / s41467-022-34643-5). In TEM8 knockout mice, tumor cell growth was significantly slowed (Nanda A., Carson-Walter EB, Seaman S., Barber TD, Stampfl J., Singh S., Vogelstein B., Kinzler KW, St Croix B. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI) Cancer Res. 2004; 64:817–820. doi:10.1158 / 0008-5472.can-03-2408). Furthermore, blocking the binding of TEM8 to collagen fibers with a TEM8-specific antibody demonstrated antitumor efficacy in various tumor models, including melanoma, lung cancer, and colorectal cancer.

[0007] Unlike VEGF, VEGFRs, and other angiogenic factors, TEM8 does not affect physiological angiogenesis, and TEM8 knockout mice have no effect on normal vascular development and wound healing (Cullen M, Seaman S, Chaudhary A, Yang MY, Hilton MB, Logsdon D, et al.. Host-Derived Tumor Endothelial Marker 8 (TEM8) Promotes the Growth of Melanoma. Cancer Res (2009) 69:6021–6. doi:10.1158 / 0008-5472.CAN-09-1086). These studies indicate that TEM8 has the potential to become a new target for tumor therapy, and that antibodies with high affinity and specificity for TEM8 have promising clinical applications. The present invention utilizes a fully human phage library to discover and identify TEM8-specific antibodies and explore their application prospects.

[0008] Although certain anti-TEM8 antibodies have been developed, there is still a need for further development of TEM8 antibodies based on existing technologies, especially for developing anti-human TEM8 antibodies with high specificity, high biological activity, high endocytosis ability, and / or that can be used to prepare ADC and CAR-T.

[0009] Summary of the Invention

[0010] The present invention discloses an antibody targeting TEM8 or an antigen-binding fragment thereof and applications thereof.

[0011] The present invention therefore provides a novel antibody that binds to TEM8, and an antigen-binding fragment thereof.

[0012] In some embodiments, the anti-TEM8 antibodies of the invention have one or more or all of the following characteristics:

[0013] (1) capable of binding to TEM8 with high affinity, such as binding to human, cynomolgus monkey, rat or mouse TEM8;

[0014] (2) capable of binding with high affinity to TEM8 expressed on the cell membrane surface, such as TEM8 from humans, cynomolgus monkeys, rats, or mice;

[0015] (3) being able to induce endocytosis of the antibody or its fragment or a molecule comprising the antibody or its fragment (e.g., ADC) by TEM8-positive cells (e.g., CHO cells overexpressing TEM8);

[0016] (4) Ability to target and kill TEM8-positive cells, such as TEM8-positive tumor cells;

[0017] (6) capable of treating tumors such as cancer; or

[0018] (7) Suitable for constructing antibody-drug conjugates (ADCs) for targeted killing of TEM8-positive cells, such as TEM8-positive tumor cells; or for treating tumors such as cancer.

[0019] In some embodiments, the present invention provides nucleic acids encoding the antibodies or fragments thereof of the present invention, vectors comprising the nucleic acids, and host cells comprising the vectors.

[0020] In some embodiments, the present invention provides methods of making an antibody or fragment thereof of the present invention.

[0021] In some embodiments, the invention provides molecules, such as antibody drug conjugates, pharmaceutical compositions, and combination products, comprising an antibody of the invention.

[0022] The present invention also provides a method for preventing or treating a TEM8-related disease, such as a tumor such as cancer (preferably a TEM8-positive tumor, such as a TEM8-positive cancer), in a subject using the antibody of the present invention or its antibody-drug conjugate.

[0023] The present invention also relates to a method for detecting TEM8 in a sample. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 shows the construction of human and mouse TEM8 CHO stable cell lines.

[0025] FIG2 shows the EC50 of five candidate molecules binding to human and mouse TEM8 overexpressing cells as determined by FACS.

[0026] Figure 3 shows the IC50 values ​​of five antibodies detected by DT3C assay for endocytosis in human and mouse TEM8-overexpressing cells.

[0027] FIG4 shows the in vitro killing IC50 of five candidate molecules after being coupled with MMAE.

[0028] Figure 5 shows the in vivo activity of five candidate molecules after conjugation with MMAE in the HCT116 CDX model.

[0029] FIG6 shows the in vivo activity of 6A6Q naked antibody in the HCT116 CDX model.

[0030] Detailed Description of the Invention

[0031] For the purpose of explaining this specification, the following definitions will be used, and as long as appropriate, terms used in the singular may also include the plural, and vice versa. It should be understood that the present invention is not limited to the specific methodology, schemes and reagents described herein, as these may vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs.

[0032] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.

[0033] As used herein, the term "and / or" means any one of the alternatives or two or more of the alternatives.

[0034] As used herein, the terms "comprising" or "including" are intended to include the recited elements, integers, or steps, but do not exclude any other elements, integers, or steps. In this document, when the terms "comprising" or "including" are used, unless otherwise indicated, combinations of the recited elements, integers, or steps are also encompassed. For example, when reference is made to an antibody variable region "comprising" a specific sequence, it is intended to encompass an antibody variable region consisting of that specific sequence.

[0035] As used herein, the terms "anti," "binding," or "specific binding" mean that the binding is selective for the target or antigen and can be distinguished from unwanted or non-specific interactions. The ability of a binding site to bind to a specific target or antigen can be determined by flow cytometry or enzyme-linked immunosorbent assay (ELISA) or conventional binding assays known in the art, such as by radioimmunoassay (RIA) or thin-layer interferometry or MSD assays or surface plasmon resonance (SPR).

[0036] The terms "anti-TEM8 antibody," "anti-TEM8," "TEM8 antibody," or "TEM8-binding antibody" as used herein refer to antibodies that are capable of binding to (primate, such as human or cynomolgus monkey, or mouse or rat) TEM8 or a fragment thereof with sufficient affinity.

[0037] An "isolated" antibody or molecule is one that has been separated from a component of its natural environment. In some embodiments, the antibody or molecule is purified to greater than 95% or 99% purity, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC).

[0038] The terms "whole antibody" or "full-length antibody" are used interchangeably herein and refer to antibody molecules with the structure of natural immunoglobulin molecules. In the case of conventional four-chain IgG antibodies, the full-length antibody comprises two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. In the case of heavy chain antibodies having only heavy chains and lacking light chains, the full-length antibody comprises two heavy chains (H) interconnected by disulfide bonds. For conventional four-chain IgG antibodies, the full-length antibody heavy chain is generally composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region, wherein the heavy chain constant region comprises at least three domains CH1, CH2 and CH3. The full-length antibody light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region, wherein the light chain constant region consists of one domain CL. Each heavy chain variable region VH and each light chain variable region are composed of three CDRs and four FRs, arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In some embodiments, the antibody that Unchained sells to you is a full-length antibody, such as a conventional four-chain IgG full-length antibody.

[0039] The term "antibody fragment" includes a portion of an intact antibody. In preferred embodiments, the antibody fragment is an antigen-binding fragment. The term "antigen-binding fragment" of an antibody refers to a molecule, distinct from a full-length antibody, that comprises a portion of a full-length antibody but is capable of binding to the antigen of the full-length antibody or competing with the full-length antibody (i.e., the full-length antibody from which the antigen-binding fragment is derived) for antigen binding. Antigen-binding fragments can be prepared by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, dAb (domain antibody), linear antibodies, single-chain antibodies (e.g., scFv); single-domain antibodies such as VHH, diabodies or fragments thereof, or camelid antibodies, diabodies, single-domain antibodies (sdAb), and nanobodies. For example, Fab fragments can be obtained by papain digestion of a full-length antibody. In addition, digestion of a full-length antibody below the disulfide bonds in the hinge region by pepsin produces F(ab')2, a dimer of Fab', a divalent antibody fragment. F(ab')2 can be reduced under neutral conditions by breaking the disulfide bond in the hinge region, thereby converting the F(ab')2 dimer into a Fab' monomer. The Fv fragment consists of the VL and VH domains of a single antibody arm. The two domains of the Fv fragment, VL and VH, can be encoded by independent genes, but recombinant methods can also be used to connect the two domains using a synthetic linker peptide to produce them as a single protein chain, and in the single protein chain, the VL region and the VH region are paired to form a single-chain Fv (scFv).

[0040] "Complementarity determining region" or "CDR region" or "CDR" is a region in an antibody variable domain that is highly variable in sequence and forms structurally determined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of the heavy and light chains are typically referred to as CDR1, CDR2, and CDR3, and are numbered sequentially starting from the N-terminus. The CDRs located within the antibody heavy chain variable domain are referred to as HCDR1, HCDR2, and HCDR3, while the CDRs located within the antibody light chain variable domain are referred to as LCDR1, LCDR2, and LCDR3.In a given light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment schemes, including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of the CDR loops (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Accessing the Kabat antibody sequence database by computer; Martin et al., "Structures of the CDRs", Journal of Molecular Biology, 273, 927-948 (1997)), and Kabat based on antibody sequence variability (Accessing the Kabat antibody sequence database by computer; Martin et al., "Structures of the CDRs", Journal of Molecular Biology, 273, 927-948 (1997)). AC; Proteins, 1996 May; 25(1): 130-3; doi: 10.1002 / (SICI)1097-0134(199605)25: 1<130::AID-PROT11>3.0.CO; 2-L. ​​PMID: 8727325), AbM (University of Bath), Contact (University College London), the international ImMunoGeneTics database (IMGT) (IMGT, the international ImMunoGeneTics information system, http: / / imgt.cines.fr; Lefranc MP; Novartis Found Symp. 2003; 254: 126-36; discussion 136-42, 216-22, 250-2. PMID: 14712935 Review), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures.

[0041] In some embodiments, the CDRs of the heavy chain variable region of the antibodies of the present invention are determined according to Kabat or IMGT. In some embodiments, the CDRs of the light chain variable region of the antibodies of the present invention are determined according to Kabat or IMGT.

[0042] Unless otherwise indicated herein, amino acid residue numbering in the Fc or heavy chain constant region is according to the EU numbering system (also called the EU index) as described in Kabat et al., Sequences of Proteins of Immunological Interes, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD, 1991, NIH Publication 91-3242; amino acid residue numbering in the light and heavy chain variable regions is according to the Kabat numbering system (also called the Kabat index) as described in Kabat et al., Sequences of Proteins of Immunological Interes, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD, 1991, NIH Publication 91-3242.

[0043] The term "amino acid substitution" is used interchangeably herein and refers to the replacement of at least one amino acid residue in a predetermined parent amino acid sequence with a different "substituted" amino acid residue. The replacement residue or residues can be a "naturally occurring amino acid residue" (i.e., encoded by the genetic code) and are selected from the group consisting of: alanine (Ala); arginine (Arg); asparagine (Asn); aspartic acid (Asp); cysteine ​​(Cys); glutamine (Gln); glutamic acid (Glu); glycine (Gly); histidine (His); isoleucine (Ile); leucine (Leu); lysine (Lys); methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); threonine (Thr); tryptophan (Trp); tyrosine (Tyr); and valine (Val). The definition of amino acid substitution herein also encompasses substitution with one or more non-naturally occurring amino acid residues. "Non-natural amino acid residues" refer to residues that are capable of covalently binding to adjacent amino acid residues in a polypeptide chain, in addition to those naturally occurring amino acid residues listed above. Examples of non-natural amino acid residues include norleucine, ornithine, norvaline, homoserine, Aib and other amino acid residue analogs.

[0044] As used herein, "conservative changes" include substitutions, deletions, or additions to a polypeptide sequence that do not substantially alter the desired functional activity of the polypeptide sequence. In some embodiments, conservative changes are conservative substitutions. Conservative substitutions refer to the replacement of one amino acid with another amino acid within the same class, such as the replacement of an acidic amino acid with another acidic amino acid, the replacement of a basic amino acid with another basic amino acid, or the replacement of a neutral amino acid with another neutral amino acid. For example, conservative substitutions often result in the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following lists 8 groups of amino acids containing conservative substitutions for each other: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine ​​(C), Methionine (M). In some embodiments, the term "conservative change" when applied to an antibody molecule amino acid sequence refers to an amino acid modification that does not significantly affect or change the target antigen binding characteristics of the antibody molecule of the present invention containing the amino acid sequence. For example, a conservatively changed variant maintains at least 80%, 85%, 90%, 95%, 98%, 99% or higher, such as 100-110% or higher, binding affinity for the target antigen relative to the parent antibody.

[0045] The term "therapeutic agent" as used herein encompasses any substance effective in preventing or treating tumors, such as cancer, including chemotherapeutic agents, cytokines, cytotoxic agents, other antibodies, small molecule drugs, or immunomodulators (eg, immunosuppressants).

[0046] "Chemotherapeutic agents" include chemical compounds useful in treating cancer or immune system disorders.

[0047] The term "small molecule drug" refers to low molecular weight organic compounds that are capable of regulating biological processes. "Small molecules" are defined as molecules with a molecular weight of less than 10 kD, typically less than 2 kD, and preferably less than 10 kD. Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing inorganic components, molecules containing radioactive atoms, synthetic molecules, peptide mimetics, and antibody mimics. As therapeutic agents, small molecules can be more cell-permeable, less susceptible to degradation, and less prone to eliciting an immune response than macromolecules.

[0048] As used herein, the term "immunomodulator" refers to a natural or synthetic agent or drug that inhibits or modulates an immune response. The immune response can be a humoral response or a cellular response. Immunomodulators include immunosuppressants. In some embodiments, the immunomodulators of the present invention include immune checkpoint inhibitors or immune checkpoint agonists.

[0049] "Isolated nucleic acid encoding an anti-TEM8 antibody or a fragment thereof" refers to one or more nucleic acid molecules that encode an antibody heavy chain or light chain (or a fragment thereof, such as a heavy chain variable region or a light chain variable region), including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present at one or more locations in a host cell.

[0050] "Percent identity (%)" of an amino acid sequence refers to the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the specific amino acid sequence set forth in this specification, after aligning the candidate sequence with the specific amino acid sequence set forth in this specification and introducing gaps, if necessary, to achieve the maximum percentage identity, and not considering any conservative substitutions as part of the sequence identity. In some embodiments, the present invention contemplates variants of the antibody molecules of the present invention that have a substantial degree of identity, e.g., at least 80%, 85%, 90%, 95%, 97%, 98% or 99% or more, relative to the antibody molecules and sequences thereof specifically disclosed herein. Such variants may comprise conservative changes.

[0051] The term "pharmaceutical excipient" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, carrier, stabilizer, or the like, which is administered together with the active substance.

[0052] The term "label" as used herein refers to a compound or composition that is directly or indirectly conjugated or fused to a reagent (such as a polynucleotide probe or antibody) and promotes the detection of the reagent to which it is conjugated or fused. The label itself can be detectable (e.g., a radioisotope label or a fluorescent label) or can catalyze a chemical change in a detectable substrate compound or composition in the case of an enzymatic label. The term is intended to encompass direct labeling of a probe or antibody by coupling (i.e., physically connecting) a detectable substance to the probe or antibody and indirect labeling of the probe or antibody by reacting with another reagent of the direct label.

[0053] The term "combination therapy" refers to the administration of two or more therapeutic agents or treatment modalities to treat diseases described herein. This administration includes co-administering these therapeutic agents in a substantially simultaneous manner, such as in a single capsule with a fixed ratio of active ingredients. Alternatively, this administration includes co-administration of each active ingredient in a variety of or separate containers (such as tablets, capsules, powders, and liquids). The powder and / or liquid can be reconstituted or diluted to the desired dose before administration. In addition, this administration also includes using each type of therapeutic agent in a sequential manner at approximately the same time or at different times. In either case, the therapeutic regimen will provide the beneficial effects of the drug combination in treating disorders or conditions described herein.

[0054] As used herein, "treat," ..."

[0055] As used herein, "prevention" includes the inhibition of the onset or development of a disease or condition or symptoms of a particular disease or condition.

[0056] "Subject / patient / individual sample" refers to a collection of cells or fluids obtained from a patient or subject. The source of a tissue or cell sample can be solid tissue, such as a sample from a fresh, frozen and / or preserved organ or tissue sample or a biopsy sample or a puncture sample; blood or any blood component; body fluids, such as tears, vitreous humor, cerebrospinal fluid, amniotic fluid (amniotic fluid), peritoneal fluid (ascites), or interstitial fluid; cells from any time during the subject's pregnancy or development. Tissue samples may contain compounds that are not naturally contaminated with tissue in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc.

[0057] The first aspect of the present invention provides an antibody or a fragment thereof (eg, an antigen-binding fragment) that specifically binds to TEM8.

[0058] In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention comprise three complementarity determining regions (HCDRs) from the heavy chain variable region, HCDR1, HCDR2, and HCDR3. In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention comprise three complementarity determining regions (LCDRs) from the light chain variable region, LCDR1, LCDR2, and LCDR3. In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention comprise three complementarity determining regions (HCDRs) from the heavy chain variable region and three complementarity determining regions (LCDRs) from the light chain variable region.

[0059] In some aspects, the anti-TEM8 antibodies of the present invention or its antigen-binding fragments thereof comprise a heavy chain variable region (VH). In some aspects, the anti-TEM8 antibodies of the present invention or its antigen-binding fragments thereof comprise a light chain variable region (VL). In some aspects, the anti-TEM8 antibodies of the present invention or its antigen-binding fragments thereof comprise a heavy chain variable region (VH) and a light chain variable region (VL). In some embodiments, the heavy chain variable region comprises 3 complementary determining regions (HCDRs) from the heavy chain variable region, HCDR1, HCDR2 and HCDR3. In some embodiments, the light chain variable region comprises 3 complementary determining regions (LCDRs) from the light chain variable region, LCDR1, LCDR2 and LCDR3.

[0060] In some embodiments, the heavy chain variable region of the present invention

[0061] (i) comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 1, 14, 27, 42 or 55; or

[0062] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 1, 14, 27, 42 or 55; or

[0063] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (e.g., conservative changes, such as amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 1, 14, 27, 42 or 55, preferably, the amino acid changes do not occur in the CDR regions.

[0064] In some embodiments, the light chain variable region of the present invention

[0065] (i) comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 2, 15, 28, 40, 43 or 56; or

[0066] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 2, 15, 28, 40, 43 or 56; or

[0067] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, 1) amino acid changes (e.g., conservative changes, such as amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 2, 15, 28, 40, 43 or 56, preferably, the amino acid changes do not occur in the CDR regions.

[0068] In some embodiments, the three complementarity determining regions (HCDRs) of the present invention, HCDR1, HCDR2, and HCDR3, from the heavy chain variable region are selected from

[0069] (i) three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO: 1, 14, 27, 42 or 55, or

[0070] (ii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid change (preferably an amino acid substitution, preferably a conservative substitution) in the three HCDR regions relative to the sequence of any one of (i),

[0071] Wherein the HCDRs may be determined according to any CDR assignment scheme, such as the assignment schemes of Kabat, AbM, Chothia or IMGT, respectively, or a combination thereof, respectively, for example, the HCDRs are determined according to IMGT or Kabat, respectively.

[0072] In some embodiments, the three complementarity determining regions (LCDRs) of the present invention, LCDR1, LCDR2, and LCDR3, from the light chain variable region are selected from

[0073] (i) three complementary determining regions LCDR1, LCDR2 and LCDR3 contained in the VL as shown in SEQ ID NO: 2, 15, 28, 40, 43 or 56,

[0074] or

[0075] (ii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid alteration (preferably an amino acid substitution, preferably a conservative substitution) in the three LCDR regions relative to the sequence of any one of (i),

[0076] Wherein the LCDRs can be determined according to any CDR assignment scheme, such as the assignment schemes of Kabat, AbM, Chothia or IMGT, respectively, or a combination thereof, respectively, for example, the LCDRs are determined according to IMGT or Kabat, respectively.

[0077] In some embodiments, the HCDR1 determined based on IMGT comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 3, 16, 29, 44, or 57, or the HCDR1 determined based on IMGT comprises an amino acid sequence having one, two, or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 3, 16, 29, 44, or 57.

[0078] In some embodiments, the HCDR1 determined based on Kabat comprises the amino acid sequence shown in any one of SEQ ID NO: 9, 22, 35, 50 or 63, or consists of the amino acid sequence, or the HCDR1 determined based on Kabat comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NO: 9, 22, 35, 50 or 63.

[0079] In some embodiments, the HCDR2 determined based on IMGT comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 4, 17, 30, 45, or 58, or the HCDR2 determined based on IMGT comprises an amino acid sequence having one, two, or three alterations (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 4, 17, 30, 45, or 58.

[0080] In some embodiments, the HCDR2 determined based on Kabat comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 10, 23, 36, 51 or 64, or the HCDR2 determined based on Kabat comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 10, 23, 36, 51 or 64.

[0081] In some embodiments, the HCDR3 determined based on IMGT comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 5, 18, 31, 46, or 59, or the HCDR3 determined based on IMGT comprises an amino acid sequence having one, two, or three alterations (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 5, 18, 31, 46, or 59.

[0082] In some embodiments, the HCDR3 determined based on Kabat comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 11, 24, 37, 52, or 65, or the HCDR3 determined based on Kabat comprises an amino acid sequence having one, two, or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 11, 24, 37, 52, or 65.

[0083] In some embodiments, LCDR1 determined based on IMGT comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 6, 19, 32, 47, or 60, or LCDR1 determined based on IMGT comprises an amino acid sequence having one, two, or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 6, 19, 32, 47, or 60.

[0084] In some embodiments, LCDR1 determined based on Kabat comprises the amino acid sequence shown in any one of SEQ ID NO: 12, 25, 38, 53 or 66, or consists of the amino acid sequence, or LCDR1 determined based on Kabat comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NO: 12, 25, 38, 53 or 66.

[0085] In some embodiments, the LCDR2 determined based on IMGT comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 7, 20, 33, 48, or 61, or the LCDR2 determined based on IMGT comprises an amino acid sequence having one, two, or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 7, 20, 33, 48, or 61.

[0086] In some embodiments, LCDR2 determined based on Kabat comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 13, 26, 39, 54, or 67, or LCDR2 determined based on Kabat comprises an amino acid sequence having one, two, or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 13, 26, 39, 54, or 67.

[0087] In some embodiments, the LCDR3 determined based on IMGT comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 8, 21, 34, 41, 49, or 62, or the LCDR3 determined based on IMGT comprises an amino acid sequence having one, two, or three alterations (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 8, 21, 34, 41, 49, or 62.

[0088] In some embodiments, the LCDR3 determined based on Kabat comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 8, 21, 34, 41, 49, or 62, or the LCDR3 determined based on Kabat comprises an amino acid sequence having one, two, or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence shown in any one of SEQ ID NOs: 8, 21, 34, 41, 49, or 62.

[0089] In some specific embodiments of the present invention, the anti-TEM8 antibody or antigen-binding fragment thereof of the present invention comprises:

[0090] 1) the three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 1, and the three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 2;

[0091] 2) three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 14, and three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 15;

[0092] 3) the three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 27, and the three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 28 or 40;

[0093] 4) the three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO:42, and the three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO:43; or

[0094] 5) three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in VH as shown in SEQ ID NO: 55, and three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in VL as shown in SEQ ID NO: 56,

[0095] For example, wherein the HCDR and the LCDR are determined according to the IMGT or Kabat scheme.

[0096] In some specific embodiments of the present invention, the anti-TEM8 antibody or antigen-binding fragment thereof of the present invention comprises: three complementarity determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region, and three complementarity determining regions LCDR1, LCDR2 and LCDR3 of the light chain variable region, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 respectively comprise or consist of the amino acid sequence shown in the following table SEQ ID NO based on the IMGT scheme:

[0097] Or wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are based on the Kabat scheme, and each comprises or consists of the amino acid sequence shown in the following table SEQ ID NO:

[0098] In some specific embodiments of the present invention, the anti-TEM8 antibody or antigen-binding fragment thereof of the present invention comprises VH and VL, wherein VH and VL respectively comprise the amino acid sequence as set forth in the SEQ ID NO listed in the following table, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence as set forth in the SEQ ID NO listed in the following table, or consist of the amino acid sequence:

[0099] In a preferred embodiment, the present invention provides an anti-TEM8 antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region respectively comprise or consist of the amino acid sequence shown in the following table SEQ ID NO:

[0100] In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention further comprise an antibody heavy chain constant region. In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention further comprise an antibody light chain constant region. In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention further comprise a heavy chain constant region and a light chain constant region.

[0101] In some embodiments, the heavy chain constant region of the antibody of the present invention is the heavy chain constant region of IgG1, IgG2, IgG3 or IgG4, preferably the heavy chain constant region of IgG1. In some embodiments, the light chain constant region of the antibody of the present invention is the light chain constant region of λ or Kappa.

[0102] In some preferred embodiments, the heavy chain constant region of the antibody of the present invention is

[0103] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 71;

[0104] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 71; or

[0105] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (e.g., conservative changes, such as amino acid substitutions, more preferably conservative amino acid substitutions) compared to the amino acid sequence selected from SEQ ID NO: 71.

[0106] In some embodiments, the antibody light chain constant region of the invention is

[0107] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 72 or 73;

[0108] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 72 or 73; or

[0109] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (e.g., conservative changes, such as amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 72 or 73.

[0110] In some embodiments, the antibodies or fragments thereof of the present invention comprise a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO: 71, or consists of the amino acid sequence, and the light chain constant region comprises the amino acid sequence shown in SEQ ID NO: 72 or 73, or consists of the amino acid sequence.

[0111] In some embodiments, the anti-TEM8 antibodies of the present invention or their antigen-binding fragments comprise an antibody heavy chain (HC). In some embodiments, the anti-TEM8 antibodies of the present invention or their antigen-binding fragments further comprise an antibody light chain (LC). In some embodiments, the anti-TEM8 antibodies of the present invention or their antigen-binding fragments comprise a heavy chain and a light chain. In some embodiments, the antibody heavy chain of the present invention comprises an antibody heavy chain variable region and an antibody heavy chain constant region or consists of a heavy chain variable region and a heavy chain constant region. In some embodiments, the antibody light chain of the present invention comprises an antibody light chain variable region and an antibody light chain constant region or consists of a heavy chain variable region and a heavy chain constant region. In some embodiments, the antibody of the present invention comprises two heavy chains and two light chains, or consists of two heavy chains and two light chains, for example, the two heavy chains are identical and the two light chains are identical.

[0112] In some embodiments, the antibodies of the present invention comprise a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region, and the light chain comprises a light chain variable region and a light chain constant region, wherein

[0113] (i) the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 1, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 2, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the heavy chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 71, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: The amino acid sequence of NO:72, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, or consisting of said amino acid sequence;

[0114] (ii) the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 14, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 15, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the heavy chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 71, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: The amino acid sequence of NO:72, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, or consisting of said amino acid sequence;

[0115] (iii) the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 27, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 28 or 40, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the heavy chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 71, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: The amino acid sequence of NO:73, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, or consisting of said amino acid sequence;

[0116] (iv) the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 42, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 43, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the heavy chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 71, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: The amino acid sequence of NO:73, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, or consisting of said amino acid sequence; or

[0117] (v) the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 55, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 56, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, the heavy chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 71, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain constant region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: The amino acid sequence shown in NO:73 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, or consisting of said amino acid sequence.

[0118] In some embodiments, the antibodies of the present invention comprise a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region, and the light chain comprises a light chain variable region and a light chain constant region, wherein

[0119] (vi) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 1, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 2, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 72;

[0120] (vii) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 14, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 15, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 72;

[0121] (viii) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 27, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 28 or 40, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 73;

[0122] (ix) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 42, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 43, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 73; or

[0123] (x) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 55, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 56, the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 73.

[0124] In one embodiment of the invention, the amino acid changes described herein are conservative changes. In one embodiment of the invention, the amino acid changes described herein include amino acid substitutions, insertions or deletions. Preferably, the amino acid changes described herein are amino acid substitutions, preferably conservative substitutions.

[0125] In a preferred embodiment, the amino acid changes described herein occur in regions outside of the CDRs (e.g., in the FRs). More preferably, the amino acid changes described herein occur in regions outside of the heavy chain variable region and / or outside of the light chain variable region.

[0126] In some embodiments, the substitution is a conservative substitution. A conservative substitution refers to the substitution of one amino acid by another amino acid within the same class, such as an acidic amino acid by another acidic amino acid, a basic amino acid by another basic amino acid, or a neutral amino acid by another neutral amino acid.

[0127] In certain embodiments, substitution occurs in the CDR regions of an antibody. Typically, the variants obtained have modifications (e.g., improvements) relative to certain biological properties of the parent antibody (e.g., increased affinity) and / or will have certain biological properties that are substantially retained of the parent antibody.

[0128] In some embodiments, the antibodies provided herein are modified to remove glycosylation sites. In some embodiments, the glycosylation site NRS of the antibodies of the present invention or fragments thereof is removed, preferably by mutation, such as by mutation to QRS.

[0129] In certain embodiments, it may be desirable to generate cysteine ​​engineered antibodies, eg, "thioMAbs," in which one or more residues of an antibody are substituted with cysteine ​​residues.

[0130] In certain embodiments, the antibodies provided herein may be further modified to contain other non-proteinaceous moieties known in the art and readily available. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.

[0131] In some embodiments, the anti-TEM8 antibodies or antigen-binding fragments thereof of the present invention further include antibodies or antigen-binding fragments having one or more of the following properties:

[0132] (1) exhibiting the same or similar binding affinity and / or specificity for TEM8 as any of the antibodies listed in the present invention;

[0133] (2) inhibiting the binding of any antibody listed in the present invention to TEM8;

[0134] (3) binds to the same or overlapping epitope as any of the antibodies described herein; or

[0135] (4) Compete with any of the antibodies shown in the present invention for binding to TEM8.

[0136] As defined herein, an "antibody that binds to the same or overlapping epitope as a reference antibody" is an antibody that blocks 50%, 60%, 70%, 80%, 90% or 95% or more of the binding of the reference antibody to its antigen in a competition assay, whereas conversely, the reference antibody blocks 50%, 60%, 70%, 80%, 90% or 95% or more of the binding of the antibody to its antigen in a competition assay.

[0137] As defined herein, an antibody that competes with a reference antibody for binding to its antigen is an antibody that blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the reference antibody to its antigen in a competition assay. Conversely, a reference antibody blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the antibody to its antigen in a competition assay. Numerous types of competitive binding assays can be used to determine whether one antibody competes with another, such as solid phase direct or indirect radioimmunoassays (RIAs), solid phase direct or indirect enzyme immunoassays (EIAs), sandwich competition assays, biointerferometry (e.g., Fortebio), or surface plasmon resonance (Biacore).

[0138] As defined herein, an antibody that inhibits (e.g., competitively inhibits) the binding of a reference antibody to its antigen is an antibody that inhibits the binding of the reference antibody to its antigen by 50%, 60%, 70%, 80%, 90%, or 95% or more. Conversely, a reference antibody inhibits the binding of the antibody to its antigen by 50%, 60%, 70%, 80%, 90%, or 95% or more. The binding of an antibody to its antigen can be measured by affinity (e.g., equilibrium dissociation constant). Methods for determining affinity are known in the art.

[0139] An antibody that exhibits the same or similar binding affinity and / or specificity as a reference antibody is an antibody that has at least 50%, 60%, 70%, 80%, 90% or more than 95% of the binding affinity and / or specificity of the reference antibody. This can be determined by any method known in the art for determining binding affinity and / or specificity.

[0140] In some embodiments, the anti-TEM8 antibody is a monoclonal antibody.

[0141] In some embodiments, the anti-TEM8 antibody is a human antibody.

[0142] In some embodiments, the anti-TEM8 antibody is a full-length antibody.

[0143] In one embodiment, the anti-TEM8 antibodies of the present invention also encompass antibody fragments thereof, such as antigen-binding fragments thereof. In some embodiments, the antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, single-chain Fv, diabody, single-domain antibody (sdAb), nanobody, or sc(Fv)2.

[0144] In certain embodiments, anti-TEM8 antibody molecules are in the form of bispecific or multispecific antibody molecules. In one embodiment, bispecific antibodies can bind to two different epitopes of TEM8 protein. In one embodiment, bispecific antibodies can bind to TEM8 and another protein. Therefore, the anti-TEM8 antibodies of the present invention also encompass multispecific antibodies such as bispecific antibodies that specifically bind to TEM8 and other antigens.

[0145] Therefore, in some embodiments, the present invention relates to a bispecific antibody or multispecific antibody that specifically binds to TEM8 and one or more other antigens.

[0146] The second aspect of the present invention is to provide an antibody-drug conjugate comprising the anti-TEM8 antibody or antigen-binding fragment thereof of the present invention.

[0147] The antibodies or fragments thereof of the present invention can induce TEM8-positive cells to internalize the antibodies or fragments thereof or molecules comprising the antibodies or fragments thereof, and are therefore suitable for use in constructing antibody-drug conjugates.

[0148] In some embodiments, the present invention provides an antibody drug conjugate comprising any anti-TEM8 antibody provided herein and other substances, such as therapeutic agents or labels. In some embodiments, the therapeutic agent is a cytotoxic agent. In some embodiments, the therapeutic agent is MMAE.

[0149] In some embodiments, an antibody or antigen-binding fragment thereof of the present invention is linked to a cytotoxic agent (e.g., MMAE) via a linker to form an antibody-drug conjugate. In some embodiments, the linker is a Vc linker. In some embodiments, an antibody or antigen-binding fragment thereof of the present invention is linked to a VcMMAE to form an antibody-drug conjugate.

[0150] In a third aspect of the present invention, a nucleic acid, such as an isolated nucleic acid molecule, encoding the anti-TEM8 antibody of the present invention or a fragment thereof or either chain thereof is provided.

[0151] For example, nucleic acids of the invention include nucleic acids encoding an amino acid sequence selected from any one of SEQ ID NOs: 1, 2, 14, 15, 27, 28, 40, 42, 43, 55, or 56, or nucleic acids encoding an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from any one of SEQ ID NOs: 1, 2, 14, 15, 27, 28, 40, 42, 43, 55, or 56. As will be appreciated by those skilled in the art, due to codon degeneracy, each antibody or polypeptide amino acid sequence can be encoded by multiple nucleic acid sequences. Nucleic acid sequences encoding molecules of the invention can be generated using methods well known in the art, such as de novo solid phase DNA synthesis or PCR amplification.

[0152] When expressing from a suitable expression vector, the polypeptide by said nucleic acid encoding can show people (and / or mouse, rat, dog or cynomolgus monkey) TEM8 antigen binding ability.For example, in some embodiments, the nucleic acid of the variable region of said coding heavy chain and / or light chain is operably connected with the nucleic acid of the constant region of coding heavy chain and / or light chain in frame, thereby when expressing from a suitable expression vector, produce the nucleic acid of coding said antibody heavy chain and / or.

[0153] To facilitate production and purification, a secretory signal peptide and / or a tag peptide that facilitates purification, such as a his tag, can be fused to the N-terminus of the heavy chain and / or light chain of the antibody.

[0154] In a fourth aspect of the present invention, one or more vectors comprising the nucleic acid of the present invention are provided.

[0155] The term "vector" as used herein refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is attached when used herein. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which it has been introduced. The term "expression vector" refers to a vector comprising a recombinant polynucleotide that comprises an expression control sequence that is operably linked to the nucleotide sequence to be expressed. The expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be provided by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) into which recombinant polynucleotides are incorporated.

[0156] In one embodiment, the vector is an expression vector, such as a eukaryotic expression vector. Vectors include but are not limited to viruses, plasmids, cosmids, lambda phages, or yeast artificial chromosomes (YACs). In one embodiment, the vector is a pCDNA vector, such as pCDNA3.4.

[0157] In a fifth aspect of the present invention, a host cell comprising a nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention, or a vector comprising the nucleic acid is provided.

[0158] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include primary transformed cells and progeny derived therefrom, without considering the number of passages. Progeny may not be completely identical to the parent cell in nucleic acid content, but may contain mutations. Included herein are mutant progeny with the same function or biological activity that have been screened or selected in the initially transformed cells. Host cells are any type of cell system that can be used to produce the antibody molecules of the present invention, including eukaryotic cells, for example, mammalian cells, insect cells, yeast cells; and prokaryotic cells, for example, Escherichia coli cells. Host cells include cultured cells, as well as cells within transgenic animals, transgenic plants, or cultured plant tissues or animal tissues.

[0159] In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells, mammalian cells (e.g., CHO cells (e.g., CHO-S or CHO-K or CHO-K1) or 293 cells (e.g., 293T, 293F or HEK293 cells)) or other cells suitable for preparing antibodies or fragments thereof. In one embodiment, the host cell is prokaryotic, for example, a bacterium, such as Escherichia coli.

[0160] In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells, mammalian cells or other cells suitable for preparing antibodies or their fragments. For example, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding antibodies. Vertebrate cells can also be used as hosts. For example, mammalian cell lines modified to be suitable for suspension growth can be used. Other examples of useful mammalian host cell lines are monkey kidney CV1 lines (COS-7) transformed with SV40; human embryonic kidney lines (HEK293, 293F or 293T cells) and the like. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including CHO-S cells or CHO-K or CHO-K1, etc.; and myeloma cell lines such as Y0, NS0 and Sp2 / 0. Mammalian host cell lines suitable for producing antibodies are known in the art.

[0161] In a sixth aspect of the present invention, the present invention provides a method for preparing an anti-TEM8 antibody or fragment thereof (preferably an antigen-binding fragment), wherein the method comprises culturing the host cell under conditions suitable for expressing a nucleic acid encoding the antibody or fragment thereof (preferably an antigen-binding fragment) or either one or both chains thereof, and optionally isolating the antibody or fragment thereof (preferably an antigen-binding fragment). In a certain embodiment, the method further comprises recovering the anti-TEM8 antibody or fragment thereof (preferably an antigen-binding fragment) from the host cell.

[0162] The polynucleotide encoding the polypeptide chains of the antibodies or antigen-binding fragments thereof of the present invention can be inserted into one or more vectors for further cloning and / or expression in host cells. Methods well known to those skilled in the art can be used to construct expression vectors. Once an expression vector comprising one or more nucleic acid molecules of the present invention has been prepared for expression, the expression vector can be transfected or introduced into a suitable host cell. A variety of techniques can be used to achieve this purpose, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, liposome-based transfection or other conventional techniques.

[0163] Antibodies prepared as described herein can be purified by known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, e.g., Protein A, size exclusion chromatography, etc. The actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, hydrophilicity, etc., and these will be apparent to those skilled in the art.

[0164] The purity of the antibody molecules of the present invention can be determined by any of a number of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like.

[0165] In a seventh aspect of the present invention, methods or assays are provided for identifying, screening or characterizing the physical / chemical properties and / or biological activities of the anti-TEM8 antibodies provided herein.

[0166] In one aspect, the antibodies of the invention are tested for their antigen binding activity, for example, by known methods such as thin-layer interferometry, ELISA, etc. Binding to TEM8 can be determined using methods known in the art, for example, using radioimmunoassay (RIA) or thin-layer interferometry (BLI) or electrochemiluminescence (ECL) or surface plasmon resonance (SPR) or flow cytometry (FACS) measurements.

[0167] The present invention also provides an assay for identifying anti-TEM8 antibodies having biological activity. The biological activity is selected from the properties of the antibodies of the present invention and can include, for example, binding to TEM8 (e.g., binding to human, cynomolgus monkey, mouse and / or rat TEM8), endocytic activity, or cytotoxicity against TEM8-positive cells.

[0168] For example, the binding activity of the antibody molecules of the present invention to TEM8 or cells expressing TEM8 can be determined by methods known in the art, such as Fortebio, flow cytometry, Octet or plasma resonance (Biacore), or the exemplary method disclosed in Example 3 herein.

[0169] For example, the endocytic activity of the antibody molecules of the present invention against cells (eg, TEM8-positive cells, eg, TEM8-overexpressing cells) can be determined by methods known in the art, such as DT3C, or the exemplary method disclosed in Example 4 herein.

[0170] For example, the cell-killing activity or anti-tumor activity of the antibody molecules of the present invention or antibody drug conjugates comprising the same against cells (e.g., TEM8-positive cells, such as tumor cells) can be determined by methods known in the art, such as cell killing assays, such as in vitro cell killing assays, or in vivo animal model assays, or the exemplary methods disclosed in Examples 7, 8, or 9 herein.

[0171] Cells for use in any of the above in vitro assays include cell lines that naturally express TEM8 or are engineered to express TEM8. Such cells also include cell lines that express TEM8 and cell lines transfected with TEM8-encoding DNA that do not normally express TEM8, such as the HCT116 cell line.

[0172] It will be appreciated that any of the above assays can be performed using the antibody drug conjugates of the present invention in place of or in addition to the anti-TEM8 antibody.

[0173] It will be appreciated that any of the above assays can be performed using anti-TEM8 antibodies in combination with additional active agents.

[0174] In an eighth aspect of the present invention, a composition, such as a pharmaceutical composition or pharmaceutical preparation, is provided, which comprises the antibody or antigen-binding fragment thereof or antibody-drug conjugate thereof of the present invention.

[0175] As used herein, the term "pharmaceutical composition" refers to a composition that is in a form that permits the biological activity of the active ingredient contained therein to be effective, and that contains no additional ingredients that are unacceptably toxic to a subject to which the composition would be administered.

[0176] In some embodiments, the pharmaceutical composition or pharmaceutical formulation further comprises a pharmaceutical excipient, such as a pharmaceutical carrier, a pharmaceutical excipient, including a buffer, as known in the art. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, isotonic agents, and absorption delaying agents that are physiologically compatible.

[0177] For the use of pharmaceutical excipients and their applications, see also "Handbook of Pharmaceutical Excipients", 8th edition, RC Rowe, PJ Eskey and S C Owen, Pharmaceutical Press, London, Chicago.

[0178] The compositions or formulations of the present invention can be in a variety of forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable solutions and infusible solutions), powders or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic use.

[0179] Pharmaceutical formulations comprising the antibodies described herein can be prepared by mixing the antibodies of the invention having the desired degree of purity with one or more pharmaceutical excipients, preferably in the form of a lyophilized formulation or an aqueous solution.

[0180] The pharmaceutical composition of the present invention or preparation can also comprise more than a kind of active ingredient, and described active ingredient is required for the specific indication being treated, preferably has those active ingredients of complementary activity that can not adversely affect each other.For example, it is desirable to also provide other therapeutic agents, such as chemotherapeutics, cytokines, cytotoxic agents, other antibodies, small molecule drugs or immunomodulators (such as immunosuppressants).Described active ingredient is suitably combined with the effective amount for purpose use and exists.

[0181] In the ninth aspect of the present invention, a drug combination or drug combination product is provided, which comprises an anti-TEM8 antibody or fragment thereof (preferably an antigen-binding fragment) of the present invention, or an antibody-drug conjugate thereof, and one or more other therapeutic agents (e.g., chemotherapeutic agents, cytokines, cytotoxic agents, other antibodies, vaccines, small molecule drugs or immunomodulators (e.g., immunosuppressants).

[0182] As used herein, the term "drug combination or combination product" refers to a non-fixed combination product or a fixed combination product, including but not limited to a kit / test kit. The term "non-fixed combination" means that the active ingredients (e.g., (i) an antibody of the invention or its antibody drug conjugate, and (ii) other therapeutic agent) are administered to a patient simultaneously, without specific time restrictions, or sequentially at the same or different time intervals, as separate entities, wherein such administration provides prophylactically or therapeutically effective levels of two or more active agents in the patient's body. The term "fixed combination" means that two or more active agents are administered to a patient simultaneously in the form of a single entity. The dosage and / or time interval of the two or more active agents are preferably selected so that the combined use of the parts can produce an effect greater than that achieved by using any one component alone when treating a disease or condition. Each component can be in the form of a separate formulation, which can be the same or different.

[0183] In a tenth aspect of the present invention, a kit is provided, comprising the pharmaceutical combination of the present invention, preferably in the form of a pharmaceutical dosage unit, whereby dosage units can be provided according to a dosing regimen or a drug administration interval.

[0184] In one embodiment, the kit of parts of the present invention comprises in the same package:

[0185] - a first container containing a pharmaceutical composition comprising an anti-TEM8 antibody or fragment thereof or an antibody-drug conjugate thereof;

[0186] - A second container containing a pharmaceutical composition comprising another therapeutic agent, such as a chemotherapeutic agent, a cytokine, a cytotoxic agent, another antibody, a vaccine, a small molecule drug, or an immunomodulatory agent (e.g., an immunosuppressant).

[0187] In the eleventh aspect of the present invention, a method for preventing or treating a TEM8-related disease in a subject is provided, comprising administering to the subject an effective amount (e.g., a preventively effective amount or a therapeutically effective amount) of an anti-TEM8 antibody or antigen-binding fragment thereof, antibody-drug conjugate, pharmaceutical composition or combination product of the present invention.

[0188] As used herein, "treat," ..."

[0189] As used herein, "prevention" includes the inhibition of the onset or development of a disease or condition or symptoms of a particular disease or condition.

[0190] As used herein, the term "effective amount" refers to an amount or dosage of an antibody or fragment or composition or combination of the present invention that produces the desired effect in a patient in need of treatment or prevention after administration in single or multiple doses to the patient.

[0191] As used herein, a "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the desired dosage and for the desired period of time. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the antibody or antibody fragment or composition or combination are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor volume) or improves a measurable parameter by at least about 40%, even more preferably by at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 100%, relative to an untreated subject.

[0192] As used herein, a "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic result at the required dosage and for the required period of time. Typically, a prophylactic effective amount will be less than a therapeutically effective amount because a prophylactic dose is used in a subject prior to or at an earlier stage of the disease.

[0193] "Individual" or "subject" or "object" includes mammals. Mammals include, but are not limited to, domestic animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the individual or subject is a human.

[0194] In some embodiments, the TEM8-related disease described herein is a disease associated with abnormal growth and / or dysfunction of tumor stromal cells, such as a tumor, such as cancer.

[0195] In some embodiments, the TEM8-related diseases described herein include tumors, such as cancer. The cancer can be in the early, middle or late stages or be a metastatic cancer. In some embodiments, the cancer can be a solid tumor or a hematological tumor. In some embodiments, the cancer is selected from colon cancer, rectal cancer or colorectal cancer.

[0196] In one embodiment, the tumor refers to a tumor tissue or tumor cells of an individual, for example, compared with adjacent normal tissue or normal cells of the individual (e.g., normal cells in the tissue) or the same tissue or cells therein of a healthy individual, having TEM8 expression or TEM8 nucleic acid, or having increased protein levels (e.g., expression) of TEM8, or increased nucleic acid levels of TEM8.

[0197] In some embodiments, the antibodies or antibody fragments or antibody drug conjugates or compositions or formulations or combination products of the invention delay the onset of a disorder and / or symptoms associated with the disorder.

[0198] In some embodiments, the prophylactic or therapeutic methods described herein further comprise administering to the subject or individual an antibody molecule or pharmaceutical composition or antibody drug conjugate disclosed herein in combination with one or more other therapies, such as treatment modalities and / or other therapeutic agents.

[0199] In some embodiments, treatment modalities include surgery, radiation therapy (e.g., external beam radiation therapy, which involves three-dimensional conformal radiation therapy in which the irradiation area is designed), local irradiation (e.g., irradiation directed to a preselected target or organ), or focused irradiation), etc.

[0200] In some embodiments, the therapeutic agent is selected from a chemotherapeutic agent, a cytokine, a cytotoxic agent, other antibodies, a vaccine, a small molecule drug, or an immunomodulator (eg, an immunosuppressant), among others.

[0201] In some embodiments, the antibodies described herein can be combined with other antibodies for separate administration, e.g., each as a separate antibody, or when linked (e.g., as a bispecific or multispecific antibody molecule).

[0202] Combination therapies of the invention encompass both combined administration (e.g., two or more therapeutic agents contained in the same formulation or separate formulations), and separate administration, in which case administration of the antibodies of the invention (as well as antibody drug conjugates, compositions, pharmaceutical compositions, formulations, etc. comprising the same) can occur prior to, concurrently with, and / or after administration of the additional therapeutic and / or pharmaceutical agents.

[0203] The anti-TEM8 antibodies of the present invention (and antibody drug conjugates, compositions, pharmaceutical compositions, preparations, combination products, etc. comprising the same) can be administered by any suitable method, including parenteral administration, and, if local treatment requires, intralesional administration. Parenteral injection or infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous injection or infusion. Depending on whether the medication is short-term or long-term to a certain extent, any suitable route, such as by injection, such as intravenous or subcutaneous injection, can be used. Various medication schedules are contemplated herein, including, but not limited to, single administration or multiple administrations at multiple time points, push administration, and pulse infusion.

[0204] In other aspects, the present invention provides the use of the anti-TEM8 antibody or fragment thereof, or an antibody-drug conjugate or composition comprising the same, in the production or preparation of a medicament for the purposes described herein, such as for preventing or treating the relevant diseases or conditions mentioned herein.

[0205] In the twelfth aspect of the present invention, the present invention also relates to methods for diagnosis and detection of the antibodies or antigen-binding fragments thereof of the present invention and compositions for diagnosis and detection comprising the same.

[0206] In certain embodiments, any of the anti-TEM8 antibodies or antigen-binding fragments thereof provided herein can be used to detect the presence of TEM8 in a biological sample.

[0207] The term "detection" as used herein includes quantitative or qualitative detection, and exemplary detection methods can involve immunohistochemistry, immunocytochemistry, flow cytometry (e.g., FACS), magnetic beads of antibody molecule complexes, ELISA assays, PCR-techniques (e.g., RT-PCR). In certain embodiments, the biological sample is other liquid samples of blood, serum, or biological origin. In certain embodiments, the biological sample comprises cells or tissues. In some embodiments, the biological sample is from tumor tissue or cancer tissue.

[0208] In one embodiment, an anti-TEM8 antibody or antigen-binding fragment thereof is provided for use in a diagnostic or detection method.

[0209] In yet another aspect, a method for detecting the presence of TEM8 in a biological sample is provided. In certain embodiments, the method comprises detecting the presence of TEM8 protein in a biological sample. In certain embodiments, TEM8 is human TEM8 or mouse, rat, dog or cynomolgus monkey TEM8. In certain embodiments, the method comprises contacting the biological sample with an anti-TEM8 antibody as described herein under the conditions allowing anti-TEM8 antibody to be combined with TEM8, and detecting whether a complex is formed between the anti-TEM8 antibody and TEM8. The formation of the complex represents the presence of TEM8. The method can be an in vitro or in vivo method. In one embodiment, the anti-TEM8 antibody is used to select an experimenter suitable for the treatment of the anti-TEM8 antibody, for example, wherein TEM8 is a biomarker for selecting the experimenter.

[0210] In certain embodiments, labeled antibodies or fragments thereof are provided. Labels include, but are not limited to, directly detected labels or moieties (such as fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels), as well as indirectly detected moieties, such as enzymes or ligands, e.g., by enzymatic reactions or molecular interactions.

[0211] In some embodiments provided herein, the sample is obtained prior to treatment with an antibody or fragment thereof of the present invention. In some embodiments, the sample is obtained prior to treatment with an alternative therapy. In some embodiments, the sample is obtained during treatment with an alternative therapy, or after treatment with an alternative therapy.

[0212] In some embodiments, TEM8 is detected prior to treatment, eg, prior to initiation of treatment or prior to a treatment following a treatment interval.

[0213] In some embodiments, a method for treating a TEM8-related disease of the present invention is provided, the method comprising: testing a subject (e.g., a sample) (e.g., a subject sample) for the presence of TEM8, thereby determining a TEM8 value, comparing the TEM8 value with a control value (e.g., the same tissue or cell of a healthy individual or the value in adjacent normal tissue or cells of the patient to be tested), and if the TEM8 value is greater than the control value, administering to the subject a therapeutically effective amount of the antibody or fragment thereof of the present invention, or an antibody-drug conjugate, composition, pharmaceutical composition, formulation or combination product comprising the same, optionally in combination with one or more other therapies, thereby treating the disease.

[0214] In the thirteenth aspect of the present invention, the present invention relates to the following specific embodiments:

[0215] 1. An antibody or antigen-binding fragment thereof that specifically binds to TEM8, the antibody comprising

[0216] 1) the three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 1, and the three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 2;

[0217] 2) three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 14, and three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 15;

[0218] 3) the three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 27, and the three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 28 or 40;

[0219] 4) the three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO:42, and the three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO:43; or

[0220] 5) three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 55, and three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 56;

[0221] Preferably, wherein said HCDR and said LCDR are determined according to the IMGT or Kabat scheme.

[0222] 2. An antibody or antigen-binding fragment thereof that specifically binds to TEM8, the antibody comprising three complementarity determining regions (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region, and three complementarity determining regions (LCDR1, LCDR2, and LCDR3) of a light chain variable region, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are based on the IMGT protocol and each comprises or consists of the amino acid sequence shown in the following table:

[0223] Or wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are based on the Kabat scheme, and each comprises or consists of the amino acid sequence shown in the following table SEQ ID NO:

[0224] 3. An antibody or antigen-binding fragment thereof that binds to TEM8 according to embodiment 1 or 2, wherein the antibody comprises a heavy chain variable region, wherein the heavy chain variable region comprises, or consists of, an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 14, 27, 42 or 55; or the heavy chain variable region comprises, or consists of, an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 14, 27, 42 or 55; and / or

[0225] The antibody comprises a light chain variable region, wherein the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 15, 28, 40, 43 or 56, or consists of said sequence; or the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 15, 28, 40, 43 or 56, or consists of said sequence.

[0226] 4. An antibody or antigen-binding fragment thereof that binds to TEM8, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein

[0227] (i) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 2;

[0228] (ii) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 14, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 15;

[0229] (iii) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 27, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 28 or 40;

[0230] (iv) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:42, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:43;

[0231] (v) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:55, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:56.

[0232] 5. The antibody or antigen-binding fragment thereof that binds to TEM8 according to embodiment 1 or 2, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region respectively comprise or consist of the amino acid sequence shown in SEQ ID NO in the following table:

[0233] 6. An antibody or antigen-binding fragment thereof that binds to TEM8 as described in any one of embodiments 1-5, wherein the antibody comprises a heavy chain constant region, such as a heavy chain constant region of IgG1, IgG2, IgG3, or IgG4, such as a heavy chain constant region of IgG1,

[0234] (i) comprises an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 71; or

[0235] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 71.

[0236] 7. An antibody or antigen-binding fragment thereof that binds to TEM8 as described in any one of embodiments 1-6, wherein the antibody comprises a light chain constant region, such as a λ or κ light chain constant region, such as the light chain constant region

[0237] (i) comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 72 or 73; or

[0238] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 72 or 73.

[0239] 8. An antibody or antigen-binding fragment thereof that binds to TEM8 as described in any one of embodiments 1-7, wherein the antibody comprises a heavy chain constant region and a light chain constant region, wherein

[0240] The heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71; and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 72 or 73.

[0241] 9. An antibody or antigen-binding fragment thereof that binds to TEM8 as described in any one of embodiments 1-8, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region, and the light chain comprises a light chain variable region and a light chain constant region, wherein

[0242] (i) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 1, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 2, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 72;

[0243] (ii) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 14, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 15, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 72;

[0244] (iii) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 27, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 28 or 40, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 73;

[0245] (iv) the heavy chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 42, the light chain variable region comprises or consists of the amino acid sequence of SEQ ID NO: 43, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 73; or

[0246] (v) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 55, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 56, the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 73.

[0247] 10. The antibody or antigen-binding fragment thereof that binds to TEM8 according to any one of embodiments 1-8, which has one or more of the following characteristics:

[0248] (1) capable of binding to TEM8 with high affinity, such as binding to human, cynomolgus monkey, rat or mouse TEM8;

[0249] (2) capable of binding with high affinity to TEM8 expressed on the cell membrane surface, such as TEM8 from humans, cynomolgus monkeys, rats, or mice;

[0250] (3) being able to induce endocytosis of the antibody or its fragment or a molecule comprising the antibody or its fragment (e.g., ADC) by TEM8-positive cells (e.g., CHO cells overexpressing TEM8);

[0251] (4) Ability to target and kill TEM8-positive cells, such as TEM8-positive tumor cells;

[0252] (6) Ability to treat tumors such as cancer;

[0253] (7) Suitable for constructing antibody-drug conjugates (ADCs) for targeted killing of TEM8-positive cells, such as TEM8-positive tumor cells; or for treating tumors such as cancer;

[0254] (8) inhibiting the binding of any antibody listed in Embodiment 9 to TEM8;

[0255] (9) binds to the same or overlapping epitope as any of the antibodies described in embodiment 9; or

[0256] (10) Compete with any of the antibodies shown in Embodiment 9 for binding to TEM8.

[0257] 11. The antibody or antigen-binding fragment thereof according to any one of embodiments 1-10, wherein the antibody is a monoclonal antibody.

[0258] 12. The antibody or antigen-binding fragment thereof of any one of embodiments 1-11, wherein the antibody is a human antibody.

[0259] 13. The antibody or antigen-binding fragment thereof according to any one of embodiments 1-12, wherein the antigen-binding fragment is an antibody fragment selected from the group consisting of: Fab, Fab', Fab'-SH, Fv, a single-chain antibody such as scFv, a (Fab')2 fragment, a single-domain antibody, a diabody, or a linear antibody.

[0260] 14. The antibody or antigen-binding fragment thereof of embodiment 13, wherein the single-chain antibody is scFv.

[0261] 15. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, wherein the antibody is a bispecific antibody or a multispecific antibody.

[0262] 16. An isolated nucleic acid encoding the anti-TEM8 antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15.

[0263] 17. An expression vector comprising the nucleic acid of embodiment 16.

[0264] 18. The expression vector according to embodiment 17, wherein the expression vector is a pCDNA vector, such as a pCDNA3.4 vector.

[0265] 19. A host cell comprising the nucleic acid of embodiment 16 or the expression vector of embodiment 17 or 18.

[0266] 20. The host cell of embodiment 19, wherein the host cell is prokaryotic or eukaryotic.

[0267] 21. The host cell of embodiment 20, wherein the host cell is selected from Escherichia coli cells, yeast cells, mammalian cells or other cells suitable for preparing antibodies or antigen-binding fragments thereof.

[0268] 22. The host cell of embodiment 21, wherein the host cell is a 293 cell or a CHO cell.

[0269] 23. A method for preparing an anti-TEM8 antibody or an antigen-binding fragment thereof, the method comprising culturing the host cell of any one of embodiments 19-22 under conditions suitable for expression of a nucleic acid encoding the anti-TEM8 antibody or antigen-binding fragment thereof of any one of embodiments 1 to 15, optionally isolating the antibody or antigen-binding fragment thereof, and optionally the method further comprising recovering the anti-TEM8 antibody or antigen-binding fragment thereof from the host cell.

[0270] 24. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15 and another therapeutic agent.

[0271] 25. The antibody-drug conjugate of embodiment 24, wherein the other therapeutic agent is a cytotoxic agent, such as MMAE, and optionally, the MMAE is conjugated to the antibody or its antigen-binding fragment via a Vc linker, for example, the antibody or its antigen-binding fragment is connected to VcMMAE to form an antibody-drug conjugate.

[0272] 26. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15, or the antibody-drug conjugate according to embodiment 24 or 25, and optionally a pharmaceutically acceptable excipient.

[0273] 27. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15, or the antibody-drug conjugate according to embodiment 24 or 25, and another therapeutic agent.

[0274] 28. A pharmaceutical combination comprising the antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15 or the antibody-drug conjugate according to embodiment 24 or 25, and another therapeutic agent.

[0275] 29. The pharmaceutical composition of embodiment 27 or the pharmaceutical combination of embodiment 28, wherein the other therapeutic agent is selected from a chemotherapeutic agent, a cytokine, a cytotoxic agent, another antibody, a small molecule drug or an immunomodulator (e.g., an immunosuppressant).

[0276] 30. Use of an effective amount of an anti-TEM8 antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15, or an antibody-drug conjugate according to embodiment 24 or 25, or a pharmaceutical composition according to embodiment 26 in the preparation of a medicament for preventing or treating a tumor in a subject or individual.

[0277] 31. The use of any one of embodiment 30, wherein the tumor is a solid tumor, for example, the tumor is a cancer, for example, the cancer is selected from colon cancer, rectal cancer or colorectal cancer.

[0278] 32. The use of embodiment 30 or 31, further comprising administering one or more other therapies to the subject in combination.

[0279] 33. The use of embodiment 32, wherein the therapy comprises a treatment modality and / or other therapeutic agents.

[0280] 34. The use according to embodiment 33, wherein the other therapeutic agent is selected from a chemotherapeutic agent, a cytokine, other antibodies, a cytotoxic agent, a vaccine, a small molecule drug or an immunomodulator (such as an immunosuppressant), and / or the treatment modality comprises surgical treatment and / or radiotherapy.

[0281] 35. A method for detecting TEM8 in a sample, the method comprising

[0282] (a) contacting a sample with any anti-TEM8 antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 15; and

[0283] (b) detecting formation of a complex between the anti-TEM8 antibody or antigen-binding fragment thereof and TEM8; optionally, the anti-TEM8 antibody is detectably labeled.

[0284] All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference in their entirety. Any or all features discussed above and throughout this application can be combined in various embodiments of the present invention. In addition, the materials, methods and examples described herein are only illustrative and are not intended to be restrictive. Other features, purposes and advantages of the present invention will become apparent from this specification and accompanying drawings and from the appended claims. Example:

[0285] Example 1: Species Sequence Homology of TEM8 Antigen and Construction of Stable High-Expression Cell Line

[0286] Homology analysis of TEM8 sequences from different species (human TEM8 (hTEM8, SEQ ID NO: 68), cynomolgus macaque TEM8 (CynoTEM8), mouse TEM8 (mTEM8, SEQ ID NO: 69), rat TEM8 (ratTEM8), and dog TEM8 (dogTEM8, SEQ ID NO: 70)) revealed that TEM8 is highly homologous in humans, cynomolgus macaques, mice, and rats. The extracellular region sequences of human TEM8 and cynomolgus macaque TEM8 are identical, while those of mouse TEM8 and rat TEM8 are identical, resulting in a 98.9% sequence homology between human and mouse TEM8 (see Table 1).

[0287] Table 1: Sequence homology of TEM8 in different species

[0288] The coding nucleic acids of human TEM8 (SEQ ID NO: 68) and mouse TEM8 (SEQ ID NO: 69) were cloned into the expression vector pCDNA3.1 (+) (Qingke Bioconstruction) and lipofectamine TMCHO-K1 cells (Kebai Bio, Cat: CBP60296) were transfected with 3000 transfection reagent (ThermoFisher, L3000075). 14 days after transfection, cells were sorted by flow cytometry. The primary antibody was L2 (67nM) (L2 antibody heavy chain: SEQ ID NO: 74; L2 antibody light chain: SEQ ID NO: 75), and the secondary antibody was goat anti-human IgG H&L (FITC) (abcam, ab6854). Cells with a positive rate of 2.5% were selected for culture and flow cytometric analysis was performed before the completion of the stable cell line culture. The CHO stable cells that highly express human TEM8 were named CHO-hTEM8, and the CHO stable cells that highly express mouse TEM8 were named CHO-mTEM8. CHO-hTEM8 and CHO-mTEM8 cells were analyzed by flow cytometry using the primary antibody L2 (67 nM) (L2 heavy chain: SEQ ID NO: 74; L2 light chain: SEQ ID NO: 75) and the secondary antibody goat anti-human IgG H&L (FITC) (abcam, ab6854). The results are shown in Figure 1, where the left figure shows the flow cytometry results for CHO-hTEM8 and the right figure shows the flow cytometry results for CHO-mTEM. The results showed that CHO-hTEM8 and CHO-mTEM8 cells highly expressed hTEM8 and mTEM8, respectively.

[0289] Example 2: Screening of TEM8-specific antibodies using a fully human scFv phage library

[0290] Fully human scFv phage antibody screening process: 2×10^12 phage library (CRO, human The scFv library was added to 1×10^7 CHO-K1 negative cells (Kebai Bio, Cat: CBP60296) and incubated at 4°C for 2 hours. The phage suspension after negative panning was added to 1×10^7 CHO-hTEM8 and incubated at 4°C for 2 hours. The cells were washed 8-11 times with PBS, and unbound phage were washed away by centrifugation. Phage bound to the cells were eluted with elution buffer (glycine-HCl buffer, 0.2M, pH 2.5). After three rounds of panning, the phage supernatant was tested for specific binding to the hTEM8-his antigen (hTEM8 containing six His tags) to obtain positive clones. The results are shown in Table 2.

[0291] Table 2: TEM8-specific phage clones

[0292] Five positive phage clones were sequenced and identified. The original 6A6 light chain sequence contained a glycosylation site, NRS, which was modified to QRS after mutation. The clone was named 6A6Q. The sequences of the light chain variable region and heavy chain variable region of the screened scFv are shown in the sequence listing.

[0293] Example 3. Construction of IgG Antibody and FACS Detection of Binding Activity to TEM8-Overexpressing Cells

[0294] IgG antibody preparation

[0295] The nucleic acids encoding the antibody light and heavy chain variable region sequences were cloned into expression vector pCDNA 3.4 containing the nucleic acid encoding the heavy chain constant region (SEQ ID NO: 71) or the light chain constant region (SEQ ID NO: 72; SEQ ID NO: 73) (see the table below for combinations). The vectors were co-transfected into CHO suspension cells for expression. The cell supernatant was collected and purified using a Protein A column. The purified antibodies were analyzed for size and purity by SDS-PAGE and HPLC-SEC.

[0296] Detection of IgG antibody binding activity to cells

[0297] The TEM8 overexpressing cells (CHO-hTEM8 and CHO-mTEM8) prepared in Example 1 were digested with trypsin and cultured at 1×10 6 100 μL of the solution was added to a U-bottom 96-well plate. Then, each antibody (3A3, 6A6Q, 7E3, 11B7, 3B3, L2 (L2 antibody heavy chain: SEQ ID NO: 74; L2 antibody light chain: SEQ ID NO: 75) and Anti-HEL antibody (Anti-HEL-Human IgG1, Bio-Bio, B117901) were diluted with PBS, with a starting concentration of 26.67 nM and 3-fold dilution for a total of 8 concentrations. 100 μL of diluted antibody was added to the cell plate to resuspend the cells, incubated at 4°C for 1 hour, and washed three times with PBS. The secondary antibody Anti-Human IgG H&L (FITC, abcam, ab6854) was diluted 1:2000 with PBS, and 100 μL of diluted secondary antibody was added to the cell plate to resuspend the cells, incubated at 4°C for 1 hour, and washed three times with PBS. 100 μL of PBS was added to resuspend the cells, and the binding signal was detected by FACS, and the data was analyzed using Graphpad.

[0298] The results are shown in Figure 2 . The five antibodies 3A3, 6A6Q, 7E3, 11B7, and 3B3 can all cross-bind to cells expressing human and mouse TEM8. The EC50s for binding to CHO-hTEM8 are 0.71 nM, 0.63 nM, 0.75 nM, 0.85 nM, and 1.51 nM, respectively; the EC50s for binding to CHO-mTEM8 are 1.48 nM, 1.16 nM, 1.41 nM, 1.21 nM, and 2.14 nM, respectively; and the EC50s for binding to CHO-hTEM8 and CHO-mTEM8 of the control antibody L2 are 1.72 nM and 2.84 nM, respectively.

[0299] Example 4: Antibody endocytosis experiment

[0300] The antibody endocytosis experiment uses the classic DT3C method, as follows:

[0301] TEM8-overexpressing cells (CHO-hTEM8 and CHO-mTEM8) in logarithmic growth phase were trypsinized and plated into 96-well plates at 5,000 cells / well in 100 μL of culture medium. The plates were incubated in a 37°C, 5% CO2 incubator for 24 hours. Recombinant DT3C protein (CUSABIO, CSB-EP360556CQR1) was diluted to 587 nM in cell culture medium (Ham's F-12K, 10% FBS).

[0302] Dilute the antibody to 267nM in cell culture medium. Mix the diluted recombinant DT3C protein and antibody in equal volumes to form a mixture and incubate at room temperature for 30 minutes. Dilute the mixture 3-fold with cell culture medium (Ham's F-12K, 10% FBS) for a total of 10 steps. Add 100μL of the diluted sample to the cell plate, mix well, and incubate in a 37°C, 5% CO2 constant temperature incubator for 48 hours. Add 20μL Cell Counting Kit-8 (CellorLab, CX001) and incubate in a 37°C, 5% CO2 constant temperature incubator for 3 hours. Measure the absorbance at 450nm using a microplate reader, and then analyze the data using Graphpad.

[0303] The results are shown in FIG3 . The mixture of DT3C of the five antibodies and the control antibody L2 can kill the cells, indicating that the antibodies are all internalized by the cells.

[0304] Example 5: Antibody epitope identification

[0305] Antibody epitope identification was performed using competitive ELISA, as follows:

[0306] The antibody was biotinylated using the EZ-Linker NHS kit (hermo Scientific, Cat: 20217). 2 nM of the labeled antibody was mixed with 240 nM of the unlabeled antibody at a molar ratio of 1:120. The mixture was incubated with CHO-hTEM8 cells at 4°C for 1 hour. After incubation, the cells were washed three times with PBS and the supernatant was removed by centrifugation. SA-bio secondary antibody (FITC-streptavidin conjugate (AAT Bioquest, Cat: 16910)) was added to the sample and incubated at 4°C for 1 hour and 30 minutes, followed by three washes with PBS. The supernatant was removed by centrifugation, and the cells were resuspended in 120 μL of PBS. Epitope binding was analyzed by FACS. Competitive binding was observed for 3A3, 6A6Q, 7E3, 3B3, and L2, belonging to the same antigenic determinant, Bin#1. 11B7 did not compete with any of these antibodies and belonged to a different antigenic determinant, Bin#2. The results are shown in Table 3.

[0307] Table 3: Antibody epitopes

[0308] Example 6 Preparation of TEM8 Antibody-Drug Conjugates

[0309] An appropriate amount of reducing agent (specific ingredients, source) was added to reduce the antibodies (L2, 7E3, 3A3, 6A6Q, 3B3, and 11B7) to expose the sulfhydryl groups between the antibody chains. VcMMAE (MCE, CAS No.: 646502-53-6) was dissolved in DMSO and prepared into a solution (concentration XX).

[0310] The dissolved VcMMAE was added at a molar ratio of 10:1 between the antibody and the linker-payload, and the antibody and VcMMAE were coupled together through a Michael addition reaction between the thiol group and the maleimide group on the linker.

[0311] The mixture after coupling was buffer replaced to remove residual VcMMAE. The purity and DAR (drug / antibody ratio) value after the reaction were determined by SEC (size exclusion chromatography) and HIC (hydrophobic chromatography), respectively. The coupling results of different candidate molecules are shown in Table 4.

[0312] Table 4: Preparation of TEM8 Antibody-Drug Conjugates

[0313] Example 7 ADC in vitro cell killing experiment

[0314] HCT116 cells (Nanjing Kebai, Cat: CBP60028) in the logarithmic growth phase were digested with trypsin and plated into 96-well plates at 3,000 cells / well, 100 μL, and incubated in a 37°C, 5% CO2 incubator for 24 hours. ADC was diluted in cell culture medium (Ham's F-12K, 10% FBS, AusGenex, Cat: FBS500-S) with a starting concentration of 30,000 nM and a 5-fold dilution series of 10. 10 μL of the diluted sample was added to the cell plate, mixed, and incubated in a 37°C, 5% CO2 incubator for 72 hours. 10 μL of Cell Counting Kit-8 (CellorLab, CX001) was added and incubated in a 37°C, 5% CO2 incubator for 3 hours. The absorbance at 450 nm was measured using a microplate reader. The data were analyzed using Graphpad. The in vitro killing activities of the TEM8 antibody-drug conjugates are shown in Table 5 , and the IC50 curve is shown in FIG4 .

[0315] Table 5: In vitro killing activity of TEM8 antibody-drug conjugates or linkers + toxins or toxins

[0316] Example 8 In vivo efficacy in HCT116 CDX model

[0317] A subcutaneous xenograft tumor model was established in Balb / c-nude mice (purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.) (Jiangsu Province Laboratory Animal Quality Certificate: 202223503) using HCT116 human colon cancer cells (Nanjing Kebai, Cat: CBP60028), and the in vivo efficacy of each TEM8 antibody-drug conjugate was evaluated.

[0318] Specifically, HCT116 cells were collected in the logarithmic growth phase, the culture medium was removed, and the cells were washed twice with PBS before being inoculated into the right back of Balb / c-nude mice at a seeding volume of 7.5*10^6 / 200ul / mouse (without adding Matrigel). After 12 days of inoculation, the tumor grew to an appropriate size and the tumor volume reached the standard (tumor volume > 100mm 3 Mice were randomly divided into 7 groups, with 5 animals in each group. They were blank control group (PBS), positive control L2-MMAE group, 3A3-MMAE group, 6A6-MMAE group, 7E3-MMAE group, 3B3-MMAE group, and 11B7-MMAE group. The solvent for all drugs was DPBS.

[0319] Dosing was started on the day of grouping (day 0), with an ip dosage of 5 mg / kg and a dosing frequency of twice a week (BIW) for 28 days. After starting group dosing, the body weight and tumor volume of the mice were measured 3 times a week. Each time, a vernier caliper was used to measure the size of the mouse tumor, and the volume calculation formula was V=(L×W^2) / 2, where L is the longest diameter of the tumor and W is the short diameter perpendicular to the longest diameter. On the 28th day after group dosing, that is, after the 9th dose, the experiment was terminated and all mice were euthanized.

[0320] The results are shown in Figure 5. All drug-treated groups (i.e., 3A3-MMAE group, 6A6-MMAE group, 7E3-MMAE group, 3B3-MMAE group, and 11B7-MMAE group) had significant tumor growth inhibition effects, and were statistically different from the blank control group.

[0321] Based on the data of the entire dosing cycle, the 6A6-MMAE group and the 7E3-MMAE group had more obvious advantages, and there were statistical differences between these two groups and the positive control L2-MMAE group (p=0.0107 and p=0.0163).

[0322] The final data showed that the tumor volume of the blank control group was 2478.9±637.3mm 3 The tumor volume of the positive control L2-MMAE group was 437.6±163.5mm 3 The tumor volumes of the 3A3-MMAE group, 6A6-MMAE group, 7E3-MMAE group, 3B3-MMAE group, and 11B7-MMAE group were 487.9±192.3 mm 3 、123.1±17.7mm 3 、141.9±51.9mm 3 、383.8±147.2mm 3 and 361.4±146.2mm 3 The above results indicate that each ADC drug has a strong tumor-suppressing activity.

[0323] Example 9 In vivo drug efficacy in HCT116 CDX model

[0324] A subcutaneous xenograft tumor model was established in Balb / c-nude mice (purchased from Shanghai Lingchang Biotechnology Co., Ltd.) using HCT116 human colon cancer cells (Nanjing Kebai, Cat: CBP60028), and the in vivo efficacy of the TEM8 antibody drug 6A6Q naked antibody was evaluated.

[0325] Specifically, HCT116 cells were collected in the logarithmic growth phase, the culture medium was removed, and the cells were washed twice with PBS before being inoculated into the right back of Balb / c-nude mice at a seeding volume of 1*10^7 / 200ul / mouse (without adding Matrigel). After 7 days of inoculation, the tumor grew to an appropriate size and the tumor volume reached the standard (tumor volume>100mm 3 The mice were randomly divided into two groups, each with 6 animals: blank control group (PBS) and 6A6Q naked antibody group. All drugs were dissolved in DPBS.

[0326] The drug was administered on the day of grouping (day 0) using ip at a dose of 20 mg / kg. The administration frequency was once a week (QW) and continued for 23 days.

[0327] After the start of group dosing, mouse body weight and tumor volume were measured three times a week. Tumor size was measured using a vernier caliper each time. Volume was calculated using the formula V = (L × W^2) / 2, where L is the longest diameter of the tumor and W is the shortest diameter perpendicular to the longest diameter. The experiment was terminated on day 23 after group dosing, i.e., after the fourth dose, and all mice were euthanized.

[0328] The results are shown in FIG6 . Based on the data of the entire administration cycle, the 6A6Q naked antibody administration group had a significant tumor growth inhibitory effect, which was statistically different from the blank control group (p<0.0001).

[0329] The final data showed that the tumor volume of the blank control group was 1447.5±190.8mm 3 The tumor volume of the 6A6Q naked antibody group was 776.3±52.4mm 3 The above results indicate that the TEM8 antibody drug 6A6Q naked antibody has a strong tumor inhibitory activity.

[0330] Sequence Listing

Claims

1. An antibody or an antigen-binding fragment thereof that specifically binds to TEM8, the antibody comprising 1) three complementary determining regions HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO: 1, and three complementary determining regions LCDR1, LCDR2 and LCDR3 contained in VL as shown in SEQ ID NO: 2; 2) three complementary determining regions HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO: 14, and three complementary determining regions LCDR1, LCDR2 and LCDR3 contained in VL as shown in SEQ ID NO: 15; 3) three complementary determining regions HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO: 27, and three complementary determining regions LCDR1, LCDR2 and LCDR3 contained in VL as shown in SEQ ID NO: 28 or 40; 4) the three complementary determining regions HCDR1, HCDR2 and HCDR3 contained in the VH as shown in SEQ ID NO:42, and the three complementary determining regions LCDR1, LCDR2 and LCDR3 contained in the VL as shown in SEQ ID NO:43; or 5) three complementary determining regions HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO:55, and three complementary determining regions LCDR1, LCDR2 and LCDR3 contained in VL as shown in SEQ ID NO:56; Preferably, wherein said HCDR and said LCDR are determined according to the IMGT or Kabat scheme.

2. An antibody or antigen-binding fragment thereof that specifically binds to TEM8, the antibody comprising three complementary determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region, and three complementary determining regions LCDR1, LCDR2 and LCDR3 of the light chain variable region, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are based on the IMGT scheme, and each comprises or consists of the amino acid sequence shown in the following table SEQ ID NO: Or wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are based on the Kabat scheme, and they respectively comprise or consist of the amino acid sequences shown in the following table SEQ ID NO:

3. The antibody or antigen-binding fragment thereof that binds to TEM8 according to claim 1 or 2, wherein the antibody comprises a heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 14, 27, 42 or 55, or consists of said sequence; or the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 14, 27, 42 or 55, or consists of said sequence; and / or The antibody comprises a light chain variable region, wherein the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 15, 28, 40, 43 or 56, or consists of said sequence; or the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 15, 28, 40, 43 or 56, or consists of said sequence.

4. An antibody or antigen-binding fragment thereof that binds to TEM8, the antibody comprising a heavy chain variable region and a light chain variable region, wherein (i) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:1, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:2; (ii) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:14, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:15; (iii) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:28 or 40; (iv) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:42, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:43; (v) the heavy chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:55, and the light chain variable region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:

56.

5. The antibody or antigen-binding fragment thereof that binds to TEM8 according to claim 1 or 2, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region respectively comprise or consist of the amino acid sequence shown in the following table SEQ ID NO:

6. The antibody or antigen-binding fragment thereof that binds to TEM8 according to any one of claims 1 to 5, wherein the antibody comprises a heavy chain constant region, such as a heavy chain constant region of IgG1, IgG2, IgG3 or IgG4, such as a heavy chain constant region of IgG1, (i) comprises an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO:71; or (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO:

71.

7. The antibody or antigen-binding fragment thereof that binds to TEM8 as described in any one of claims 1 to 6, wherein the antibody comprises a light chain constant region, such as a λ or κ light chain constant region, such as the light chain constant region (i) comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 72 or 73; or (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 72 or 73.

8. The antibody or antigen-binding fragment thereof that binds to TEM8 according to any one of claims 1 to 7, wherein the antibody comprises a heavy chain constant region and a light chain constant region, wherein The heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 71; and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 72 or 73.

9. The antibody or antigen-binding fragment thereof that binds to TEM8 as described in any one of claims 1 to 8, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region, and the light chain comprises a light chain variable region and a light chain constant region, wherein (i) The heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 1, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 2, and the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:

71. or consists of an amino acid sequence of The light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:72; (ii) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 14, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 15, the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 72; (iii). the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 27, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 28 or 40, the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 73; (iv). the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 42, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 43, the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 71, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO: 73; or (v). the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO:55, the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO:56, the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:71, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:

73.

10. The antibody or antigen-binding fragment thereof that binds to TEM8 according to any one of claims 1 to 8, which has one or more of the following characteristics: (1) capable of binding to TEM8 with high affinity, such as binding to TEM8 of human, cynomolgus monkey, rat or mouse; (2) capable of binding with high affinity to TEM8 expressed on the cell membrane surface, such as TEM8 from humans, cynomolgus monkeys, rats, or mice; (3) being able to induce endocytosis of an antibody or a fragment thereof or a molecule comprising the antibody or a fragment thereof (e.g., ADC) by TEM8-positive cells (e.g., CHO cells overexpressing TEM8); (4) Ability to target and kill TEM8-positive cells, such as TEM8-positive tumor cells; (6) Ability to treat tumors such as cancer; (7) Suitable for constructing antibody-drug conjugates (ADCs) for targeted killing of TEM8-positive cells, such as TEM8-positive tumor cells; or for treating tumors such as cancer; (8) inhibiting the binding of any antibody listed in claim 9 to TEM8; (9) binds to the same or overlapping epitope as any of the antibodies set forth in claim 9; or (10) Competing with any of the antibodies of claim 9 for binding to TEM8.

11. The antibody or antigen-binding fragment thereof of any one of claims 1-10, wherein the antibody is a monoclonal antibody.

12. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody is a human antibody.

13. The antibody or antigen-binding fragment thereof of any one of claims 1-12, wherein the antigen-binding fragment is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, single-chain antibodies such as scFv, (Fab')2 fragments, single domain antibodies, diabodies, or linear antibodies.

14. The antibody or antigen-binding fragment thereof of claim 13, wherein the single-chain antibody is a scFv.

15. The antibody or antigen-binding fragment thereof of claims 1-14, wherein the antibody is a bispecific antibody or a multispecific antibody.

16. An isolated nucleic acid encoding the anti-TEM8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 15.

17. An expression vector comprising the nucleic acid of claim 16.

18. The expression vector of claim 17, wherein the expression vector is a pCDNA vector, such as a pCDNA3.4 vector.

19. A host cell comprising the nucleic acid of claim 16 or the expression vector of claim 17 or 18.

20. The host cell of claim 19, wherein the host cell is prokaryotic or eukaryotic.

21. The host cell of claim 20, wherein the host cell is selected from Escherichia coli cells, yeast cells, mammalian cells, or other cells suitable for producing antibodies or antigen-binding fragments thereof.

22. The host cell of claim 21, wherein the host cell is a 293 cell or a CHO cell.

23. A method for preparing an anti-TEM8 antibody or an antigen-binding fragment thereof, the method comprising culturing the host cell of any one of claims 19-22 under conditions suitable for expressing a nucleic acid encoding the anti-TEM8 antibody or antigen-binding fragment thereof of any one of claims 1 to 15, optionally isolating the antibody or antigen-binding fragment thereof, and optionally the method further comprises recovering the anti-TEM8 antibody or antigen-binding fragment thereof from the host cell.

24. An antibody drug conjugate comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 15 and another therapeutic agent.

25. The antibody-drug conjugate of claim 24, wherein the other therapeutic agent is a cytotoxic agent, such as MMAE, and optionally, the MMAE is conjugated to the antibody or its antigen-binding fragment via a Vc linker, for example, the antibody or its antigen-binding fragment is connected to VcMMAE to form an antibody-drug conjugate.

26. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 15 or the antibody-drug conjugate according to claim 24 or 25, and optionally a pharmaceutically acceptable excipient.

27. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 15 or the antibody drug conjugate according to claim 24 or 25, and other therapeutic agents.

28. A pharmaceutical combination comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 15 or the antibody drug conjugate according to claim 24 or 25, and other therapeutic agents.

29. The pharmaceutical composition of claim 27 or the pharmaceutical combination of claim 28, wherein the other therapeutic agent is selected from a chemotherapeutic agent, a cytokine, a cytotoxic agent, other antibodies, a small molecule drug or an immunomodulator (e.g., an immunosuppressant).

30. Use of an effective amount of an anti-TEM8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, or an antibody-drug conjugate according to claim 24 or 25, or a pharmaceutical composition according to claim 26 in the preparation of a medicament for preventing or treating a tumor in a subject or an individual.

31. The use of any one of claims 30, wherein the tumor is a solid tumor, such as the tumor is a cancer, such as the cancer is selected from colon cancer, rectal cancer or colorectal cancer.

32. The use of claim 30 or 31, further comprising co-administering one or more other therapies to the subject.

33. The use of claim 32, wherein the therapy comprises a therapeutic modality and / or other therapeutic agents.

34. The use of claim 33, wherein the other therapeutic agent is selected from a chemotherapeutic agent, a cytokine, other antibodies, a cytotoxic agent, a vaccine, a small molecule drug or an immunomodulator (e.g., an immunosuppressant), and / or the treatment comprises surgery and / or radiotherapy.

35. A method for detecting TEM8 in a sample, the method comprising (a) contacting a sample with any anti-TEM8 antibody or antigen-binding fragment thereof according to any one of claims 1 to 15; and (b) detecting the formation of a complex between the anti-TEM8 antibody or antigen-binding fragment thereof and TEM8; optionally, the anti-TEM8 antibody is detectably labeled.

Citation Information

Patent Citations

  • Tem8 antibodies and their use

    CN105813654A

  • Specificity combined tumor endothelial marker 8 monoclonal antibody and application thereof

    CN106478818A

  • TEM8 antibody and application thereof

    CN110156894A

  • Antibodies to tumor endothelial marker 8

    US20130323173A1

  • TEM8 antibodies, conjugates thereof, and their use

    US20140134179A1

Cited By

  • Antxr1-binding antibody and use thereof

    WO2026205707A1